Olayioye MA, Neve RM, Lane HA, Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 19:3159- 3167, 2000 3. Samanta A, LeVea CM, Dougall WC , Qian X, Greene MI: Ligand and p185c -neu density govern receptor interactions and tyrosine kinase activation. Proc Natl Acad Sci U S A 91:1711 -1715, 1994 4. Stark A, Hulka BS, Joens S, Novotny D, Thor AD, Wold LE, Schell MJ, Melton LJ, 3rd, Liu ET, Conway K: HER -2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol 18:267- 274, 2000 5. Allred D, Clark G, Molina R, Tandon A, Schnitt S, Gilchrist K, Osborne C, Tormey D, McGuire W: Overexpression of HER -2/neu and i ts relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23:974- 979, 1992 6. Allred DC, Mohsin SK, Fuqua SA: Histological and biological evolution of human premalignant breast disease. End ocr Relat Cancer 8:47 -61, 2001 7. Craft N, Shostak Y, Carey M, CL S: A mechanism for hormone -independent prostate cancer through modulation of androgen receptor signaling by the HER -2/neu tyrosine kinase. Nat Med 5:280- 285, 1999 8. Slamon DJ, Clark GM, Won g SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER -2/neu oncogene. Science 235:177- 182, 1987 9. Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML: Vacc ination against the HER -2/neu oncogenic protein. Endocr Relat Cancer 9:33- 44, 2002 10. Zaks TZ, Rosenberg SA: Immunization with a peptide epitope (p369- 377) from HER -2/neu leads to peptide -specific cytotoxic T lymphocytes that fail to recognize HER - 2/neu+ tumors. Cancer Res 58:4902- 4908, 1998 11. Knutson KL, Schiffman K, Cheever MA, Disis ML: Immunization of cancer patients with a HER -2/neu, HLA -A2 peptide, p369- 377, results in short -lived peptide -specific immunity. Clin Cancer Res 8:1014 - 1018, 2002 12. Knutson KL, Schiffman K, Disis ML: Immunization with a HER -2/neu helper peptide vaccine generates HER - 2/neu CD8 T -cell immunity in cancer patients. J Clin Invest 107:477- 484, 2001 13. Lehmann PV, Forsthuber T, Miller A, Sercarz EE: Spreading of T -cell auto immunity to cryptic determinants of an autoantigen. Nature 358:155- 157, 1992 14. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K: Generation of T -cell immunity to the HER -2/neu protein after active immunization with HE R-2/neu peptide -based vaccines. J Clin Oncol 20:2624- 2632, 2002 15. el-Shami K, Tirosh B, Bar -Haim E, Carmon L, Vadai E, Fridkin M, Feldman M, Eisenbach L: MHC class I - restricted epitope spreading in the context of tumor rejection following vaccination wit h a single immunodominant CTL epitope. Eur J Immunol 29:3295- 3301, 1999 16. Vanderlugt CJ, Miller SD: Epitope spreading. Curr Opin Immunol 8:831- 836, 1996 17. Sercarz EE: Driver clones and determinant spreading. J Autoimmun 14:275- 277, 2000 18. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy JA, Economou JS: Determinant spreading associated with clinical response in dendritic cell -based immunotherapy for malignant melanom a. Clin Cancer Res 9:998- 1008, 2003 19. Baselga J: Herceptin alone or in combination with chemotherapy in the treatment of HER2 -positive metastatic breast cancer: pivotal trials. Oncology 61:14 -21, 2001 20. Sparano JA: Cardiac toxicity of trastuzumab (Herc eptin): implications for the design of adjuvant trials. Semin Oncol 28:20- 27, 2001 21. Fisk B, Blevins TL, Wharton JT, Ioannides CG: Identification of an immunodominant peptide of HER - 2/neu protooncogene recognized by ovarian tumor -specific cytotoxic T lym phocyte lines. J Exp Med 181:2109- 2117, 1995 6304p Protocol 118 04/06/2016 22. Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ: Tumor -specific and HLA -A2- restricted cytolysis by tumor -associated lymphocytes in human metastatic breast cancer. J Immunol 155:4486- 4491, 1995 23. Meyer zum Buschenfelde C, Nicklisch N, Rose -John S, Peschel C, Bernhard H: Generation of tumor - reactive CTL against the tumor -associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells. J Imm unol 165:4133- 4140, 2000 24. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM: Humanization of an anti -p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89:4285- 4289, 1992 25. Hurwi tz E, Stancovski I, Sela M, Yarden Y: Suppression and promotion of tumor growth by monoclonal antibodies to ErbB -2 differentially correlate with cellular uptake. Proc Natl Acad Sci U S A 92:3353 -3357, 1995 6304p Protoc ol 118 04/06/2016 Appendix A ECOG Performance Status Scale Performance status: Patients will be assessed according to the current ECOG performance scale. Grade Scale 0 Fully active: able to carry on all pre -disease performance without restriction. 1 Restricted in physically strenuous activity but ambulatory (can walk) and able to carry out work of a light or sedentary (sitting) nature, e.g. light housework, office work. 2 Ambulatory and capable of self -care but unable to carry out any work activities. Up and about more than 50% of waking hou rs. 3 Capable of only limited self -care: confined to bed or chair more than 50% of waking hours. 4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair.